CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)
CCTG would like to welcome our new Patient Representative, Catherine Wreford who will be supporting the Brain Cancer Disease Site Committee. Catherine is a professional dancer and actress who was born and raised in Winnipeg, Manitoba, Canada. In 2013, a little over a month after giving birth to her second child, Catherine was diagnosed with incurable anaplastic astrocytoma (a malignant brain tumour).
Please note that in the lead up to Family Day, CCTG Central Office will have limited coverage of critical activities only on Friday February 17th and will be closed Monday
The CCTG Annual Spring Meeting of Participants will be held Friday, April 28 to Sunday, April 30 at the Chelsea Hotel, Toronto. As we close in on the meeting, we will continue to keep you updated on all of the deadlines, so stay tuned!
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Lung Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and selection process.
